<DOC>
	<DOCNO>NCT02254369</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single oral dos GC021109 administer healthy adult subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study Single Ascending Doses GC021109 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult male and/or nonchildbearing potential female , 18 55 year age , inclusive , time informed consent . 2 . Continuous nonsmoker use nicotinecontaining product least 3 month prior dose study drug . 3 . BMI ≥ 18.5 ≤ 32.0 ( kg/m2 ) screen maximum weight 120 kg . 4 . Medically healthy clinically significant screening result would exclude subject study deem PI . 5 . Females must undergo 1 follow sterilization procedure , official documentation , least 6 month prior dose study drug : Hysteroscopic sterilization Bilateral tubal ligation bilateral salpingectomy Hysterectomy . Bilateral oophorectomy . OR postmenopausal amenorrhea least 1 year prior dose study drug folliclestimulating hormone ( FSH ) serum level consistent postmenopausal status . 6 . All male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . 7 . If male , must agree donate sperm Day 1 90 day dose . 8 . Understand study procedure ICF , willing able comply protocol . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI . 3 . History illness , opinion PI , might confound result study pose additional risk subject participation study . 4 . History presence alcoholism drug abuse within past 2 year prior screen . 5 . History presence hypersensitivity idiosyncratic reaction component study drug relate compound . 6 . History cancer within past 5 year ( exclude nonmelanoma skin cancer ) prior screen . 7 . Clinically significant abnormal screen laboratory test value ( determine PI ) , include , limited , follow : value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) upper limit reference range screen checkin . value total direct bilirubin 1.5 time upper limit reference range screen checkin . estimate creatinine clearance &lt; 90 mL/min screening . 8 . Clinically significant infection within 3 month prior screen determine PI . 9 . Female subject childbearing potential . 10 . Female subject pregnant lactating . 11 . Positive urine drug urine alcohol result screen checkin . 12 . Positive urine cotinine screening . 13 . Positive result screen HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) . 14 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 15 . Seated heart rate lower 40 bpm high 99 bpm screening . 16 . Orthostatic vital sign result deem clinically significant opinion PI screening . 17 . QTcB interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) deem clinically abnormal PI , prior dose study drug . 18 . Unable refrain anticipates use : Any drug , include prescription nonprescription medication , herbal remedy , vitamin supplement substrates CYP1A2 , CYP3B6 , CYP3A4 begin 14 day prior dose study drug throughout study . Acetaminophen ( 2 g per 24 hour period ) may permit study . Any drug know significant inducer CYP enzymes and/or Pglycoprotein ( Pgp ) , include St. John 's Wort , 28 day prior dose study drug throughout study . Appropriate source consult PI designee confirm lack PK/PD interaction study drug . 19 . Has diet incompatible onstudy diet , opinion PI , within 28 day prior dose study drug , throughout study . 20 . Has donate blood within 3 month screen visit plan donate blood within 3 month study completion , except blood collect another clinical trial perform 30 day prior screen . 21 . Plasma donation within 7 day prior dose study drug . 22 . Participation another clinical trial within 30 day prior screen . The 30day window derive date last study schedule blood collection dosing , whichever later , previous study date screen current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>